Contract analysis

I. Executive Summary This memorandum analyzes Whitmore Aerospace LLC's ("WAL") termination rights under § 14.2 of the Master Supply Agreement for Titanium Alloy Turbine Housings dated June 15, 2018 (the "MSA," reference WAL-KDG-MSA-2018-0615), entered into between WAL, as Buyer, and Kestrel Dynamics GmbH ("Kestrel"), as Seller. The analysis has been prepared at your request in connection with the pending ICC arbitrat

II. Factual Background A. The MSA and Its Key Provisions On June 15, 2018, WAL and Kestrel entered into the MSA, a comprehensive supply agreement governing the manufacture and delivery of Ti-6Al-4V ELI (Extra Low Interstitials) titanium alloy turbine housings (the "Products") for use in WAL's commercial and defense aerospace propulsion systems. The MSA was the culmination of an approximately nine-month negotiation pr

III. Legal Analysis A. Structure of § 14.2 — Two Independent Termination Pathways

Section 14.2 of the MSA provides two distinct and independent grounds upon which either party may terminate the MSA for cause. A careful reading of the provision — and its interaction with § 8.4 — demonstrates that each pathway has its own trigger, its own procedural requirements, and its own cure mechanism. The two pathways are not cumulative; satisfaction of either is independently sufficient to support termination

§ 14.2(a) — Material Breach. Under this provision, either party may terminate the MSA upon a material breach by the other party that remains uncured for a period of 60 days following written notice specifying the breach. This is a general termination-for-cause provision requiring the terminating party to: (i) identify the material breach in a written notice; and (ii) afford the breaching party a 60-day period in whic

§ 14.2(b) — Persistent Quality Failure. Under this provision, either party may terminate the MSA upon a Persistent Quality Failure, as that term is defined in § 8.4. Section 8.4 defines "Persistent Quality Failure" as the occurrence of three or more uncured lot rejections (i.e., rejections for which the non-conforming Products have not been replaced or reworked to specification within the applicable cure period) duri

1. The Persistent Quality Failure Threshold Was Met The Persistent Quality Failure threshold defined in § 8.4 — three or more uncured lot rejections in any rolling 12-month period — was unambiguously met, and indeed substantially exceeded, during the period at issue. Between March 7, 2022 (the date of the first rejection, Lot KDG-2022-0307) and September 19, 2022 (the date of the final rejection, Lot KDG-2022-0919),

2. WAL Followed Proper Procedural Steps WAL's exercise of its termination right under § 14.2(b) was procedurally proper in all respects. First, WAL's incoming inspection process for each lot was performed in strict accordance with WAL-QCP-100, the company's established quality control procedure for incoming material inspection. WAL-QCP-100 prescribes the sampling methodology, testing protocols (including CT scanning

3. The Termination Did Not Require an Additional 60-Day Cure Period A central issue likely to be raised by Kestrel is whether WAL was required to provide an additional 60-day cure period under § 14.2(a) before terminating the MSA, notwithstanding that the termination was effected under § 14.2(b). For the reasons set forth below, the answer is no. The 60-day cure provision in § 14.2(a) applies by its terms to terminat

Section 8.7 of the MSA provides that the Buyer's exclusive remedy for quality failures in delivered Products is limited to: (i) replacement of the non-conforming Products with conforming Products; (ii) a credit against future orders in the amount of the purchase price of the non-conforming Products; or (iii) upon a Persistent Quality Failure, termination of the MSA in accordance with § 14.2(b). The provision further

IV. Anticipated Counterarguments by Kestrel Based on the positions articulated in Kestrel's Request for Arbitration and the preliminary communications between counsel, WAL should anticipate and be prepared to rebut the following counterarguments. A. WAL Applied Unpublished, Stricter Porosity Specifications Kestrel is expected to argue — and has already alleged in its Request for Arbitration — that WAL's incoming insp

V. Impact on Kestrel's Damages Claims A detailed analysis of Kestrel's claimed damages is reserved for separate companion memoranda currently in preparation. However, the following brief overview is provided to illustrate the significance of the termination defense to the overall case. If the Tribunal sustains WAL's position that the termination was proper under § 14.2(b) (or, alternatively, under § 14.2(a)), the ent

VI. Support for WAL's Counterclaim WAL's counterclaim of approximately €5.17 million is supported by the analysis set forth above. Because Kestrel's quality failures triggered WAL's right to terminate under § 14.2(b), and because the termination was properly exercised, Kestrel is liable for the direct damages flowing from its breach — specifically, the incremental cost to WAL of procuring replacement turbine housings

VII. Conclusions and Recommendations Based on the foregoing analysis, I reach the following conclusions and recommendations:

1. WAL's termination of the MSA on October 3, 2022 was procedurally and substantively proper under § 14.2(b). Seven uncured lot rejections in the rolling 12-month period from March through September 2022 far exceeded the three-rejection Persistent Quality Failure threshold defined in § 8.4. WAL followed all required procedural steps, including issuance of written rejection notices and observance of the full 45-calend

2. WAL's termination would also be defensible as a termination for material breach under § 14.2(a). Kestrel's sustained pattern of non-conforming deliveries over six months, affecting fourteen lots and 1,680 units, constitutes a material breach under the Restatement (Second) of Contracts § 241 factors as adopted by New York courts. The futility of further cure is demonstrated by Kestrel's failure to even attempt cure

3. Kestrel's anticipated counterarguments regarding unpublished specifications and pretextual motive are rebutted by the documentary and expert evidence and are legally immaterial under New York law. The porosity specification of ≤0.25% is expressly stated in the contract documents; Arclight's independent testing corroborates the rejections; Valkyr's significantly higher unit price undermines the "lower-cost replacem

4. The termination defense is the linchpin of the case. If sustained, it eliminates the entirety of Kestrel's €47.3 million damages claim and supports WAL's €5.17 million counterclaim for replacement-component costs.

5. Recommendations for next steps: (a) Statement of Defense and Counterclaim. Include the termination defense and the supporting arguments set forth in this memorandum prominently in the Statement of Defense and Counterclaim, which is due to be filed on June 30, 2023. The termination defense should be presented as the primary affirmative defense, with the consequential damages waiver and the option-versus-obligation

6. Separate memoranda are in preparation to address: (a) New York law on the enforceability of consequential damages waivers, as applied to the § 8.7 waiver; (b) the recoverability of reputational damages under New York law; and (c) the renewal-period lost profits claim, including the option-versus-obligation analysis. These memoranda will be ci